-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$59.2518.43% Upside
Janux Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Janux Therapeutics, Inc.?
Janux Therapeutics, Inc. has been rated by research analysts at Stifel Nicolaus, Scotiabank, H.C. Wainwright, BTIG in the past 90 days.